Balyasny Asset Management
CPXX

Balyasny Asset Management’s CELATOR PHARMACEUTICALS INC. COMMON STOCK CPXX Stock Holding History

Balyasny Asset Management’s Portfolio CPXX Stock Details CPXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-12,650
Closed -$21K – 1619
2015
Q3 		$21K Buy
+12,650
New +$28.1K ﹤0.01% 1112

Other funds holding CPXX

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Balyasny Asset Management's CPXX Position: Q4 2015 in Review

Balyasny Asset Management sold out of CELATOR PHARMACEUTICALS INC. COMMON STOCK (CPXX) in Q4 2015, closing a stake of 12,650 shares — an estimated $21K sold.

Balyasny Asset Management first reported a position in CPXX in Q3 2015 and held it in 1 quarter. The position peaked at $21K in Q3 2015. 21 funds tracked by Wall St. Rank hold CPXX as of Q4 2015.

  • Balyasny Asset Management reported no remaining CELATOR PHARMACEUTICALS INC. COMMON STOCK position as of Q4 2015 after selling out during the quarter.
  • Balyasny Asset Management sold 12,650 CELATOR PHARMACEUTICALS INC. COMMON STOCK shares in Q4 2015, an estimated $21K.
  • Balyasny Asset Management first reported a position in CELATOR PHARMACEUTICALS INC. COMMON STOCK in Q3 2015 and held it in 1 quarter.
  • Balyasny Asset Management's CELATOR PHARMACEUTICALS INC. COMMON STOCK position peaked at $21K in Q3 2015.
  • 21 funds tracked by Wall St. Rank held CELATOR PHARMACEUTICALS INC. COMMON STOCK as of Q4 2015.

Based on Balyasny Asset Management's 13F filing for Q4 2015, filed 16 Feb 2016.